Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Boehringer Ingelheim
Express Scripts
Moodys
Merck

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Fosbretabulin

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Fosbretabulin: Patents, clinical trial progress, indications

Fosbretabulin is an investigational drug.

There have been 18 clinical trials for Fosbretabulin. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2015.

The most common disease conditions in clinical trials are Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic, and Ovarian Neoplasms. The leading clinical trial sponsors are Mateon Therapeutics, National Cancer Institute (NCI), and Case Comprehensive Cancer Center.

There are two hundred and six US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Fosbretabulin
TitleSponsorPhase
Fosbretabulin With Everolimus in Neuroendocrine Tumors With ProgressionLowell Anthony, MDPhase 1
FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian CancerMateon TherapeuticsPhase 2/Phase 3
Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid CancerMateon TherapeuticsPhase 3

See all Fosbretabulin clinical trials

Clinical Trial Summary for Fosbretabulin

Top disease conditions for Fosbretabulin
Top clinical trial sponsors for Fosbretabulin

See all Fosbretabulin clinical trials

US Patents for Fosbretabulin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fosbretabulin   Start Trial Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancer XAVIER UNIVERSITY OF LOUSIANA (New Orleans, LA)   Start Trial
Fosbretabulin   Start Trial Methods and devices for cellular transplantation Sernova Corporation (London, Ontario, CA)   Start Trial
Fosbretabulin   Start Trial Minimally toxic prodrugs LIFE SCIENCES RESEARCH PARTNERS VZW (Leuven, BE)   Start Trial
Fosbretabulin   Start Trial Pharmaceutical compositions comprising POH derivatives NeOnc Technologies, inc. (Los Angeles, CA)   Start Trial
Fosbretabulin   Start Trial Methods of obtaining geometry from images Bio-Tree Systems, Inc. (Framingham, MA)   Start Trial
Fosbretabulin   Start Trial EGFR-binding modular recognition domains Zyngenia, Inc. (Washington, DC)   Start Trial
Fosbretabulin   Start Trial Anti-tumor T cell immunity induced by high dose radiation The Board of Trustees of the Leland Stanford Junior University (Stanford, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fosbretabulin

Drugname Country Document Number Estimated Expiration Related US Patent
Fosbretabulin World Intellectual Property Organization (WIPO) 2015153252 2034-03-31   Start Trial
Fosbretabulin Australia 2010286531 2029-08-28   Start Trial
Fosbretabulin Canada 2772375 2029-08-28   Start Trial
Fosbretabulin China 102596273 2029-08-28   Start Trial
Fosbretabulin Cyprus 1119719 2029-08-28   Start Trial
Fosbretabulin Denmark 2470228 2029-08-28   Start Trial
Fosbretabulin Eurasian Patent Organization 025142 2029-08-28   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
AstraZeneca
McKesson
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.